GleamWall
中文EN

ATNM Actinium Pharmaceuticals, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1388320 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY130.6%
TTM EPS YoY130.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE55.2%
ROA23.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets24.3%
Debt / equity0.00x
Current ratio4.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-2.20x
Accruals ratio76.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$35.00M—$0$90,000———
R&D expense$4.71M$5.38M$4.20M$4.30M$4.25M$4.88M$7.70M$4.81M
SG&A expense$1.42M$2.06M$1.70M$2.12M$1.53M$2.62M$8.94M$2.69M
Operating income-$6.12M$27.57M-$5.90M-$6.41M-$5.69M-$7.50M-$16.64M-$7.50M
Net income-$5.84M$27.90M-$5.52M-$5.94M-$5.13M-$6.88M-$15.94M-$6.65M
EBITDA-$5.90M$28.00M-$5.87M-$6.86M-$5.49M-$7.30M-$16.59M-$7.92M
EPS (basic)-0.190.89-0.18—-0.16-0.22-0.51—
EPS (diluted)-0.190.89-0.18—-0.16-0.22-0.51—
Weighted avg. shares (diluted)31.44M31.41M31.24M—31.20M31.20M31.20M—
Balance sheet
Cash & equivalents$28.68M$36.47M$42.13M$48.00M$53.72M$60.26M$65.65M$73.23M
Current assets$29.49M$37.74M$43.26M$49.38M$54.37M$61.03M$66.46M$74.51M
PP&E, net$1.45M$700,000$268,000$295,000$226,000$271,000$317,000$364,000
Total assets$32.47M$40.16M$45.44M$51.77M$56.15M$63.02M$68.65M$76.90M
Current liabilities$7.37M$9.26M$7.35M$7.97M$6.83M$8.31M$7.11M$8.15M
Total liabilities$7.88M$9.86M$43.13M$43.94M$42.37M$44.00M$42.95M$44.14M
Shareholders' equity$24.59M$30.30M$2.30M$7.83M$13.78M$19.01M$25.69M$32.76M
Shares outstanding31.44M31.44M31.37M31.20M31.20M31.20M31.20M31.20M
Cash flow statement
Operating cash flow-$7.02M-$5.18M-$5.87M-$5.29M-$6.33M-$5.39M-$7.57M-$5.75M
Capital expenditure$770,000$478,000$2,000————$0
Free cash flow-$7.79M-$5.66M-$5.87M————-$5.75M
Investing cash flow-$770,000-$478,000-$2,000————$0
Financing cash flow-$3,000-$2,000-$3,000-$3,000-$209,000-$3,000-$2,000-$3,000
Depreciation & amortization$218,000$432,000$29,000-$442,000$206,000$204,000$47,000-$410,000
Stock-based compensation$136,000$118,000$11,000$10,000$109,000$197,000$8.87M$1.20M

Free plan shows the latest 8 periods; Pro shows all 64 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.